Comparative Pharmacology
Head-to-head clinical analysis: ERYC SPRINKLES versus ERYTHROCIN STEARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC SPRINKLES versus ERYTHROCIN STEARATE.
ERYC SPRINKLES vs ERYTHROCIN STEARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptidyl-tRNA. It may also act as a motilin receptor agonist, enhancing gastrointestinal motility.
Erythromycin binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It may also act as a motilin receptor agonist, stimulating gastrointestinal motility.
250-500 mg orally every 6 hours (or 333 mg every 8 hours) for adults; maximum 4 g/day.
250-500 mg orally every 6 hours for mild to moderate infections; up to 4 g/day for severe infections.
None Documented
None Documented
1.5-2.0 hours in adults with normal renal function; prolonged in neonates (2-4 hours) and patients with hepatic impairment.
1.5-2 hours in adults; prolonged to 5-6 hours in severe hepatic impairment. In anuria, half-life not significantly affected.
Primarily biliary (fecal) elimination (60-80% as unchanged drug) with approximately 5-15% renal excretion of active drug.
Primarily biliary-fecal (90-95% as unchanged drug and metabolites); renal excretion accounts for 2-15%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic